Teriparatide biosimilar (Salubris)

特立帕肽生物类似药（信立泰）

Report date: 2026/05/20 20:02:01

Base Information

Drug NameTeriparatide biosimilar (Salubris)
Drug Alias NameTeriparatide (Salubris)重组特立帕肽（信立泰）特立帕肽生物仿制药（信立泰）Recombinant Teriparatide (Salubris)rhPTH(1-34) +[11] 
ClassificationBiologics > Protein drugs > Recombinant polypeptideBiologics > Biosimilar
Mechanisms of ActionParathyroid hormone replacements
TargetsParathyroid hormone receptor
Therapy Area/IndicationsOsteoporosis, Postmenopausal
Global Approved IndicationsOsteoporosis, Postmenopausal
Approved Indications in ChinaOsteoporosis, Postmenopausal
Original Approved Country/TerritoryMainland China
Original Approved Date2019/09/29
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShenzhen Salubris Pharmaceuticals Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSuzhou Genemen Biotech Co Ltd
Inactive CompaniesXinlitai (Chengdu) Biological Technology Co LtdShenzhen Salubris Pharmaceuticals Co Ltd
Active IndicationsOsteoporosis, Postmenopausal
Inactive IndicationsN/A

Other Information

ATC CodeH05AA02
Related LinksWikipediaDrugBankKEGG